Aldioxa

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592499

CAS#: 5579-81-7

Description: Aldioxa is an Gastrointestinal Agent.


Chemical Structure

img
Aldioxa
CAS# 5579-81-7

Theoretical Analysis

MedKoo Cat#: 592499
Name: Aldioxa
CAS#: 5579-81-7
Chemical Formula: C4H7AlN4O5
Exact Mass: 218.02
Molecular Weight: 218.100
Elemental Analysis: C, 22.03; H, 3.24; Al, 12.37; N, 25.69; O, 36.68

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: RC 172; RC-172; Aldioxa

IUPAC/Chemical Name: Aluminum, ((2,5-dioxo-4-imidazolidinyl)ureato)dihydroxy-

InChi Key: JBSKYLXIYKLOLP-IXYISNAMSA-K

InChi Code: InChI=1S/C4H6N4O3.Al.2H2O/c5-3(10)6-1-2(9)8-4(11)7-1;;;/h1H,(H3,5,6,10)(H2,7,8,9,11);;2*1H2/q;+3;;/p-3/t1-;;;/m1.../s1

SMILES Code: O[Al](OC(N1)=N[C@@H](NC(N)=O)C1=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 218.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Asano T, Aida S, Suemasu S, Tahara K, Tanaka K, Mizushima T. Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia. Sci Rep. 2015 Dec 1;5:17519. doi: 10.1038/srep17519. PubMed PMID: 26620883; PubMed Central PMCID: PMC4664916.

2: Llena C, Forner L, Vento C. Anticalculus efficacy of a new dentifrice. Quintessence Int. 2009 Jun;40(6):497-501. PubMed PMID: 19587891.

3: Guillard O, Huguet F, Fauconneau B, Piriou A, Pineau A. Absence of gastrointestinal absorption or urinary excretion of aluminium from an allantoinate complex contained in two antacid formulations in patients with normal renal function. Eur J Clin Chem Clin Biochem. 1996 Aug;34(8):609-12. PubMed PMID: 8877335.

4: Uchida M, Hamura H, Takagi S, Noguchi Y, Shibata H, Honda H. [Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions]. Nihon Yakurigaku Zasshi. 1994 Mar;103(3):111-20. Japanese. PubMed PMID: 8144103.

5: Kanagawa S, Yosikawa Y, Dohi Y. [Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure]. Nihon Rinsho. 1991 Dec;49 Suppl:770-4. Japanese. PubMed PMID: 1808348.

6: Ohbayashi S, Misaki N, Bando K, Uchida M, Kawano S. [The effect of aldioxa on the formation of gastritis induced with sodium hydroxide]. Nihon Yakurigaku Zasshi. 1990 Nov;96(5):255-63. Japanese. PubMed PMID: 2279713.

7: Uchida M, Nishimura N, Misaki N, Ikarashi Y, Kobayashi M, Kawano O. [Effect of anti-ulcer drugs and PGE2 on the proliferation of rat gastric cultured cells]. Nihon Yakurigaku Zasshi. 1990 Apr;95(4):185-90. Japanese. PubMed PMID: 2370034.

8: Umemoto M, Nakamura S, Okumura S, Sekiguchi T, Nishihara T, Nishimura T, Hayashi S. [Evaluation of the anti-ulcer drugs using image analysis technology: effect of aldioxa containing preparation on the experimental gastric ulcer in rats]. Nihon Yakurigaku Zasshi. 1989 Nov;94(5):281-7. Japanese. PubMed PMID: 2613107.

9: Hirota K, Kawase M, Ohmori S. High-performance liquid chromatographic method for the determination of plasma allantoin. J Chromatogr. 1983 Oct 14;277:165-72. PubMed PMID: 6643602.

10: Sato K, Abe H, Nagai M, Ueno M. [Spectrophotometric determination of aldioxa in pharmaceutical preparations]. Yakugaku Zasshi. 1983 Oct;103(10):1100-2. Japanese. PubMed PMID: 6674489.

11: Fukawa K, Misaki N, Kawano O, Uchida M, Ohbayashi S, Irino O. [Experimental studies on gastric ulcer (5). Endoscopical evaluation of healing processes of acetic acid ulcer in rats (1). Ulcer reducing process]. Nihon Yakurigaku Zasshi. 1983 Feb;81(2):167-74. Japanese. PubMed PMID: 6687876.

12: Yamagata S, Miura K. Therapeutic effects of cetraxate against acute gastritis and acute aggravation of chronic gastritis. Endoscopic investigation by the double-blind method. Arzneimittelforschung. 1983;33(8):1191-5. PubMed PMID: 6357203.

13: CAHEN R, PESSONNIER A. [Study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. V. Effect on cicatrization of gastric ulcer]. Ann Pharm Fr. 1963 May;21:405-11. French. PubMed PMID: 14017702.

14: CAHEN R, PESSONNIER A. [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. IV. Effect on experimental drug-induced ulcer]. Ann Pharm Fr. 1963 Mar;21:215-22. French. PubMed PMID: 14017701.

15: CAHEN R, PESSONNIER A. [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. III. Anti-ulcerous effect]. Ann Pharm Fr. 1962 Sep-Oct;20:704-13. French. PubMed PMID: 14017700.

16: CAHEN R, CLEMENT JF. [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. II. Study of the gastric activity]. Ann Pharm Fr. 1962 Sep-Oct;20:693-703. French. PubMed PMID: 14017695.

17: CAHEN R, PESSONNIER A. [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity]. Ann Pharm Fr. 1962 Jul-Aug;20:623-36. French. PubMed PMID: 14017699.